Please provide your email address to receive an email when new articles are posted on . The nonsteroidal mineralocorticoid receptor antagonist finerenone reduced CV event risk by 13% for adults with ...
Finerenone reduced the combined primary endpoint of risk of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care Approximately twenty-nine ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results